[Felbinac gel for treatment of localized extra-articular rheumatic diseases--a multicenter, placebo controlled, randomized study].
281 patients with extra-articular rheumatic disorders (enthesiopathy, bursitis, tendinosis, fibrositis) and moderate or severe localized pain during rest or movement in shoulder, neck, elbow or knee were randomized into groups and treated for 14 days in a double blind study with either 1 g Felbinac Gel 3% (biphenyl acetic acid) three times daily (N = 142) or with the gel formulation only (N = 139). In 50% of the patients treated with Felbinac Gel compared to 29% of the placebo treated patients (p = 0.001), the investigator assessed the global therapeutic success to be good or very good. The magnitude of complaints judged on the basis of a visual analogous scale by patients and doctor showed a significant improvement in pain reduction during rest or activity after 14 days of treatment in the Felbinac group. The rheumatic complaints diminished equally according to patient judgement in both treatment groups and the concomitant use of paracetamol was low in both groups. No significant side-effects or changes in laboratory parameters were observed during therapy. Felbinac Gel therefore is suitable for a low-risk topical therapy of soft tissue rheumatic disorders.
Bolten
W
W
Rheumaklinik Bad Rappenau.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal; D005260:Female; D005782:Gels; D006801:Humans; D008297:Male; D008875:Middle Aged; D010147:Pain Measurement; D010648:Phenylacetates / Q000008:administration & dosage*; D011111:Polymyalgia Rheumatica / Q000188:drug therapy*; D016059:Range of Motion, Articular / Q000187:drug effects
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005782:Gels; D010648:Phenylacetates; C012776:biphenylylacetic acid
Felbinac-Gel zur Behandlung lokalisierter extraartikulärer rheumatischer Beschwerden--eine multizentrische, placebokontrollierte, randomisierte Studie.